Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Total Non-Current Liabilities (2019 - 2023)

Historic Total Non-Current Liabilities for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to $442.9 million.

  • ADC Therapeutics' Total Non-Current Liabilities rose 3048.65% to $442.9 million in Q3 2023 from the same period last year, while for Sep 2023 it was $442.9 million, marking a year-over-year increase of 3048.65%. This contributed to the annual value of $341.5 million for FY2022, which is 9025187.29% up from last year.
  • According to the latest figures from Q3 2023, ADC Therapeutics' Total Non-Current Liabilities is $442.9 million, which was up 3048.65% from $435.3 million recorded in Q2 2023.
  • Over the past 5 years, ADC Therapeutics' Total Non-Current Liabilities peaked at $442.9 million during Q3 2023, and registered a low of $6583.0 during Q4 2019.
  • For the 5-year period, ADC Therapeutics' Total Non-Current Liabilities averaged around $257.7 million, with its median value being $338.0 million (2022).
  • Per our database at Business Quant, ADC Therapeutics' Total Non-Current Liabilities soared by 34654050.88% in 2021 and then crashed by 1327.84% in 2022.
  • Quarter analysis of 5 years shows ADC Therapeutics' Total Non-Current Liabilities stood at $6583.0 in 2019, then surged by 1615.08% to $112904.0 in 2020, then surged by 298024.72% to $336.6 million in 2021, then grew by 1.45% to $341.5 million in 2022, then grew by 29.69% to $442.9 million in 2023.
  • Its Total Non-Current Liabilities stands at $442.9 million for Q3 2023, versus $435.3 million for Q2 2023 and $348.9 million for Q1 2023.